Biopharmaceutical company focused on the discovery and development of first-in-class therapies to treat central nervous system disorders of System XC-
Location: United States, Wisconsin, Milwaukee
Total raised: $31M
Investors 5
| Date | Name | Website |
| - | Aisling Ca... | aislingcap... |
| - | F-Prime Ca... | fprimecapi... |
| - | OrbiMed | orbimed.co... |
| - | Golden Ang... | goldenange... |
| - | Eight Road... | eightroads... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 30.03.2017 | Series C | $26M | - |
| 22.01.2014 | Series B | $3M | - |
| 26.02.2010 | - | $2M | - |
Mentions in press and media 10
| Date | Title | Description |
| 25.06.2025 | MU workshop helps scientists navigate biotech commercialization | A new workshop hosted by Marquette University aims to equip academic researchers with the knowledge and tools to bring their scientific discoveries out of the lab and into the marketplace. The Realities of Biotech: A Case Study in Entrepren... |
| 31.03.2017 | Term Sheet — Friday, March 31 | SCOOPS, PROFITS, IPOS, DEALS Cloudera is heavily funded. The company has raised more than $1 billion from Accel Partners, Greylock Partners, Meritech Capital Partners, Ignition Partners, T. Rowe Price, GV, In-Q-Tel, MSD Capital, and Intel C... |
| 31.03.2017 | Telkonet, Wantable, Marquette, & More: This Week’s WI Watchlist | Share Share on Facebook Share on Twitter LinkedIn Email Reprints March into April by staying current on news from Wisconsin’s innovation community, starting with these recent headlines: —Telkonet, a Waukesha-based company that develops hard... |
| 31.03.2017 | Promentis Pharmaceuticals Inks $26M Series C | MILWAUKEE, WI, Privately-held biopharmaceutical company announced it has completed a third round of equity investment totaling $26,000,000. >> Click here for more funding data on Promentis Pharmaceuticals >> To export Promen... |
| 30.03.2017 | Promentis Pharmaceuticals Closes $26M Series C Funding | Promentis Pharmaceuticals, Inc., a Milwaukee, Wisconsin-based biopharmaceutical company focused on the discovery and development of therapies to treat central nervous system disorders, completed a $26m Series C equity funding. The round was... |
| 30.03.2017 | Promentis Pharmaceuticals, Inc. Announces $26M Series C Financing and Elects Four New Board Members | Milwaukee, WI – March 30, 2017 – Promentis Pharmaceuticals, Inc., a privately-held biopharmaceutical company focused on the discovery and development of first-in-class therapies to treat central nervous system disorders, today announced it ... |
| 12.10.2016 | Promentis, Kiio, EmOpti, & More: This Week’s Wisconsin Watchlist | Share Share on Facebook Share on Twitter LinkedIn Email Reprints Take a break from raking leaves and putting up your Halloween decorations and catch up on the latest news from Wisconsin’s innovation community: —Milwaukee-based Promentis Pha... |
| 22.01.2014 | Promentis Pharmaceuticals Raises nearly $3M in Series B Financing | Promentis Pharmaceuticals, Inc., a Milwaukee, WI-based specialty pharmaceutical company developing novel compounds for schizophrenia, Parkinson’s disease and pediatric disorders including autism, raised nearly $3m in Series B financing. The... |
| 26.02.2010 | Promentis raises nearly $2M for schizophrenia drug development | Promoted Covid-19’s terrible toll on diabetes patients. What can be done? The public health crisis has undermined the economy and made people with chronic conditions more vulnerable and stressed. Learn more with a new report from Omada Heal... |
| - | Promentis raises nearly $2M for schizophrenia drug development | Early stage drug developer Promentis Pharmaceuticals has raised $1.94 million in equity to continue development of its schizophrenia therapeutics. The Series A round was led by the Marquette Golden Angels Network, which contributed $770,000... |